Close Menu

Adaptive Biotechnologies

Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.

In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.

Development revenues for the Seattle-based firm ticked up 5 percent to $15.0 million in Q3, partially offset by a 3 percent dip in sequencing revenues.

The FDA granted clearance to consumer genetic testing company Ancestry.com for the over-the-counter use of a health risk test for hereditary thrombophilia.

The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.

The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.

Of the 28 companies in the index, 22 firms saw their stock prices increase, while six firms' share prices decreased.

News items for the week of July 27, 2020. 

The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.

The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.

Pages